ZEAL stock news

ZEAL stock news. Deduplicated factual headlines, scored for importance, with entity sentiment and the sectors, countries, and asset classes affected. Updates open into the storyline.

See the full wire

20 wire items

2026-10-19 05:03:21 UTC#478462newconfirmednews

Zealand Pharma reports positive Phase 1 safety and tolerability results for KV1.3 blocker ZP9830

reutersimportance 0.50trust 0.90Zealand Pharma A/S +0.60ZP9830 +0.60

2026-10-13 22:02:43 UTC#455397duplicateconfirmednews

Zealand Pharma and Generate Biomedicines partner on AI-driven obesity and metabolic disease drug development

seeking alphaimportance 0.30trust 0.70Zealand Pharma A/S +0.40Generate Biomedicines, Inc. +0.40

2026-10-13 20:44:09 UTC#454997duplicateconfirmednews

Zealand Pharma and Generate Biomedicines enter AI-driven obesity drug partnership valued at up to $1.2 billion

reutersimportance 0.40trust 0.90Zealand Pharma A/S +0.50Generate Biomedicines, Inc. +0.50

2026-10-13 20:43:43 UTC#454968duplicateconfirmednews

Zealand Pharma and Generate Biomedicines partner on AI-driven obesity drug development in deal worth up to $1.2 billion

reutersimportance 0.40trust 0.90Zealand Pharma A/S +0.40Generate Biomedicines, Inc. +0.50Obesity 0

2026-10-13 20:27:07 UTC#454890newreportednews

Zealand Pharma and Generate Biomedicines partner on AI-driven obesity drug development in deal worth up to $1.2B, Bloomberg reports

reutersimportance 0.50trust 0.70Zealand Pharma A/S +0.40Generate Biomedicines, Inc. +0.40Bloomberg L.P. 0+1 entities

2026-10-08 11:59:00 UTC#432006updateconfirmedanalysis

Jefferies: Roche and Zealand Pharma's petrelintide trial results unlikely to shift investor sentiment

dow_jonesimportance 0.40trust 0.70Roche Holding AG -0.20Zealand Pharma A/S -0.40Jefferies Financial Group Inc. -0.10+1 entities

2026-10-07 18:31:42 UTC#427704duplicateconfirmednews

Zealand Pharma and Roche report up to 9.2% weight loss in Phase 2 petrelintide trial

reutersimportance 0.30trust 0.90Zealand Pharma A/S +0.50Roche Holding AG +0.50petrelintide +0.50

2026-10-07 18:29:36 UTC#427693duplicateconfirmednews

Zealand Pharma and Roche report 7.4%-9.2% weight loss in Phase 2 petrelintide trial

reutersimportance 0.40trust 0.90Zealand Pharma A/S +0.60Roche Holding AG +0.60petrelintide +0.60

2026-10-07 17:17:13 UTC#427263newconfirmednews

Zealand Pharma reports positive Phase 2 Zupreme-2 results for Petrelintide, initiates Phase 3a with Roche

reutersimportance 0.75trust 0.90Zealand Pharma A/S +0.80Petrelintide +0.80Zupreme-2 +0.70

2026-10-05 16:30:00 UTC#414788newconfirmedpress release

Zealand Pharma completes DKK 1.3 billion share buy-back program ahead of schedule

globenewswireimportance 0.40trust 1.00Zealand Pharma A/S +0.30Danske Bank A/S 0Denmark 0

2026-10-01 12:50:09 UTC#398729duplicateconfirmednews

Boehringer and Zealand's survodutide shows 13.1% weight loss in diabetes trial, missing investor expectations

bloombergimportance 0.30trust 0.90Boehringer Ingelheim -0.40Zealand Pharma A/S -0.40survodutide -0.40

2026-10-01 11:18:21 UTC#398072duplicateconfirmednews

Zealand Pharma shares decline as concerns over survodutide trial dropout rates persist

reutersimportance 0.30trust 0.90Zealand Pharma A/S -0.50survodutide -0.40

2026-10-01 09:48:00 UTC#397424updateconfirmednews

Zealand Pharma shares slide 8.5% as high dropout rate reported in Boehringer's survodutide obesity trial

dow_jonesimportance 0.50trust 0.80Zealand Pharma A/S -0.50Boehringer Ingelheim GmbH -0.20survodutide -0.30

2026-10-01 07:35:24 UTC#396838duplicateconfirmednews

Zealand Pharma and Boehringer Ingelheim report survodutide achieves 13.1% weight loss in Phase III trial

reutersimportance 0.40trust 0.90Zealand Pharma A/S +0.60

2026-10-01 07:30:00 UTC#396832duplicateconfirmednews

Zealand Pharma confirms survodutide hits SYNCHRONIZE-2 Phase III endpoints with 13.1% weight loss in T2D patients

globenewswireimportance 0.30trust 1.00Zealand Pharma A/S +0.50Boehringer Ingelheim GmbH +0.50survodutide +0.50+2 entities

2026-10-01 07:30:00 UTC#396830duplicateconfirmednews

Zealand Pharma's survodutide hits Phase III endpoints with 13.1% weight loss in T2D patients

tradingviewimportance 0.60trust 0.80Zealand Pharma A/S +0.70Boehringer Ingelheim +0.70survodutide +0.70+2 entities

2026-09-22 15:25:00 UTC#349958updateconfirmednews

Zealand Pharma's Phase 3 Zupreme obesity trial for petrelintide to enroll 7,000 participants

reutersimportance 0.50trust 0.90Zealand Pharma A/S +0.40Zupreme +0.30

2026-09-22 15:01:21 UTC#349815newconfirmednews

Zealand Pharma initiates global Phase 3 ZUPREME clinical program for obesity drug candidate petrelintide

reutersimportance 0.60trust 0.90Zealand Pharma A/S +0.50Petrelintide +0.50ZUPREME +0.50

2026-09-22 15:00:00 UTC#349830duplicateconfirmedpress release

Zealand Pharma initiates Phase 3 ZUPREME clinical program for obesity drug petrelintide

globenewswireimportance 0.50trust 1.00Zealand Pharma A/S +0.50petrelintide +0.50ZUPREME +0.40

2026-09-22 15:00:00 UTC#349829duplicateconfirmednews

Zealand Pharma and Roche initiate global Phase 3 ZUPREME obesity program for petrelintide

tradingviewimportance 0.40trust 0.70Zealand Pharma A/S +0.50Roche Holding AG +0.50petrelintide +0.50+1 entities